Skip to content

Treatment of ocular toxoplasmosis

Effects of intravitreal injection of toxoplasmic retinochoroiditis clindamaycin in comparison with oral conventional treatment

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2012121811581N2
Enrollment
26
Registered
2013-12-22
Start date
2012-01-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Toxoplasmic retinochoroiditis. Chorioretinal inflammation in infectious and parasitic diseases classified elsewhere

Interventions

Intervention 1: Intervention group: Clindamycin, 1/5 mg intravitreal injection, insulin syringes, from3.5 mm of limbus and maximum injection twice within two weeks. Intervention 2: Control group: stan
Treatment - Drugs
Intervention group: Clindamycin, 1/5 mg intravitreal injection, insulin syringes, from3.5 mm of limbus and maximum injection twice within two weeks.
Control group: standard treatment (oral medication):pyrimethamine and sulfadiazine and clindamaycin)- capsule & tablet - six months

Sponsors

Arak University of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: All patients (men and women) with retinochoroditis, Exclusion criteria: Pregnant women and patients with extensive infection in the macula and around the optic nerve.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Visual acuity. Timepoint: First Month: Weekly -Second Month: biweekly - Following months: monthly. Method of measurement: Senllene Chart.

Secondary

MeasureTime frame
Retinal thickness. Timepoint: First Month: Weekly -Second Month: biweekly - Following months: monthly. Method of measurement: OCT (Ocular Coherence Tomography).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbdollah Rashidi

Arak University of Medical Science

rashidi1382@gmail.com+98 86 3222 2191

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026